Colorectal cancer is the second most common cause of cancer-related death in the United
States. Approximately 30% to 40% of patients with colorectal cancer have locoregionally …

During the past decade, there have been several significant advances in the treatment of
metastatic colorectal cancer. These include the introduction of the cytotoxic agents …

Background: The relevance of oncology trial results to clinical practice depends on whether
the trial participants are similar to the actual population of patients receiving treatment for the …

Currently there are three targeted therapies approved for the treatment of colorectal cancers.
These include the epidermal growth factor receptor (EGFR) inhibitors, cetuximab and …

The majority of colorectal cancer patients receive chemotherapy either to palliate advanced
unresectable disease or to reduce the risk of recurrence after radical surgery. Thanks to the …

Abstract Learning Objectives After completing this course, the reader should be able to: Use
the evolving treatment strategies in metastatic colorectal cancer, including key data from …

Aim: This study was designed to determine the efficacy and tolerability of capecitabine,
oxaliplatin and bevacizumab in combination with cetuximab as first-line therapy for …

First-, second-, and third-line therapies for the treatment of metastatic colorectal cancer may
influence choices for subsequent therapy. First-line treatment for metastatic colorectal …

Colorectal cancer accounts for the death of more than 55,000 individuals in the United
States each year. 1 The vast majority of these patients receive systemic chemotherapy with …

3556 Background: Bevacizumab (BV), a monoclonal antibody directed against vascular
endothelial growth factor, provides a survival advantage when added to first line therapy for …